Publications by authors named "M Gerometta"

Claim this Profile
E
Evaluation of NUN-004, a Novel Engineered Ephrin Antagonist, in Healthy Volunteers and Patients with Amyotrophic Lateral Sclerosis: A Phase I/Ib, Open-Label, Escalating Dose and Extended Access Study.
Michael Gerometta, Robert D Henderson, Richard Friend, Leanne T Cooper, Jing Zhao

Clin Drug Investig· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vascular Endothelial Growth Factor C and D Signaling Pathways as Potential Targets for the Treatment of Neovascular Age-Related Macular Degeneration: A Narrative Review.
Ian M Leitch, Michael Gerometta, David Eichenbaum, Robert P Finger, Nathan C Steinle

Ophthalmol Ther· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Randomized Controlled Trial of OPT-302, a VEGF-C/D Inhibitor for Neovascular Age-Related Macular Degeneration.
Timothy L Jackson, Jason Slakter, Marc Buyse, Kun Wang, Pravin U Dugel, Michael Gerometta

Ophthalmology· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comprehensive approach to the protection and controlled release of extremely oxygen sensitive probiotics using edible polysaccharide-based coatings.
Thị-Thanh-Trúc Phùng, Massimiliano Gerometta, Julie Chanut, Audrey Raise, María Ureña

Int J Biol Macromol· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, tolerability, pharmacokinetics, and immunogenicity of a human monoclonal antibody targeting the G glycoprotein of henipaviruses in healthy adults: a first-in-human, randomised, controlled, phase 1 study.
Elliott Geoffrey Playford, Trent Munro, Stephen M Mahler, Suzanne Elliott, Michael Gerometta

Lancet Infect Dis· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis